Trial Profile
A 12-week with possible extension, prospective, multicenter, randomised, double-blind, controlled, 2-parallel groups, phase 2b/3 study to compare efficacy and safety of masitinib to placebo, in the treatment of moderate Crohn's disease in patients intolerant or with unsatisfactory response to immunosuppressive drugs and/or TNF-inhibitors
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 18 Jan 2023
Price :
$35
*
At a glance
- Drugs Masitinib (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Sponsors AB Science
- 18 Jan 2023 This trial has been discontinued in Belgium according to European Clinical Trials Database record.
- 21 Sep 2017 This trial has been suspended in Slovakia.
- 13 May 2017 This trial has been discontinued in Greece (end date: 10 Feb 2017).